Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

7.540 -0.330 (-4.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 Next >
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Via Benzinga
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?
DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. 
Via InvestorPlace
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.) 
Via Benzinga
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
Via Benzinga
Recap: Bayer Q4 Earnings
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM. Here's what investors need to know about the announcement. Earnings Bayer beat... 
Via Benzinga
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products
Via Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend
These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. 
Via InvestorPlace
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off
Via Benzinga
Three Stocks To Buy In This Bear Market
There’s a silver lining to the current bear market. It’s created great buying opportunities. 
Via Talk Markets
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. 
Via Benzinga
Investment Strategy Monthly Insights, April 2022
After four decades of low inflation, developed economies are grappling with an inflation spike. 
Via Talk Markets
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
Merck shares hit a six-month high Tuesday on the bullish projection. 
Via Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm. 
Via InvestorPlace
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present new long-term progression-free survival (PFS) data from the Phase 3 TIVO-3 study in kidney cancer at the 2022... 
Via Benzinga
Why Are Evotec Shares Trading Lower On Friday?
Bayer AG (OTC: BAYRY) has  
Via Benzinga
The Journey To Rewrite Human DNA Is About To Get Wild, Thanks To Pfizer, Bayer, Intellia And Other CRISPR stocks
Big Pharma is paying attention to CRISPR stocks. Could that alight shares this year? 
Via Investor's Business Daily
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
Pfizer and Bayer inked deals with several companies in gene-editing. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.